# Characterizing Epitope Binding Regions of Entire Antibody Panels by Combining Experimental and Computational Analysis of Antibody: Antigen Binding Competition 

Benjamin D. Brooks ${ }^{1,2,3, *}$, Adam Closmore ${ }^{4}$, Juechen Yang ${ }^{5}$, Michael Holland ${ }^{5}$, Tina Cairns ${ }^{3}$, Gary H. Cohen ${ }^{3}$ and Chris Bailey-Kellogg ${ }^{6}$<br>1 Department of Biomedical Sciences, Rocky Vista University, Ivins, UT 84738, USA<br>2 Inovan Inc., Fargo, ND 58102, USA<br>3 Department of Microbiology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; tmcairns@upenn.edu (T.C.); ghc@upenn.edu (G.H.C.)<br>${ }^{4}$ Department of Pharmacy, North Dakota State University, Fargo, ND 58102, USA; Adam.Closmore@gmail.com<br>5 Department of Biomedical Engineering, North Dakota State University, Fargo, ND 58102, USA; juechen.yang@gmail.com (J.Y.); mchollandred@gmail.com (M.H.)<br>6 Computer Science Department, Dartmouth College, Hanover, NH 03755, USA; cbk@cs.dartmouth.edu<br>* Correspondence: bbrooks@rvu.edu; Tel.: +1-435-222-1403

| Community | gD <br> mAb | Serotype | Neutralizing <br> Activity | Fabs <br> murine/ <br> recombinant | Epitope <br> Residues <br> (experimental) |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | E317 | Common | Yes | Commercial | $38,132,139$, <br> $140,215,222$, <br> 235 |
|  | DL11 | Common | Yes | $+/+$ | $38,132,140$ |
|  | MC23 | Common | Yes | $+/+$ | 213,216 |
|  | MC2 | Type-2 | Yes | $+/+$ | $67,243-246$, <br> 248 |
|  | MC5 | Common | Yes | $+/+$ | $54,75-77$ |
| MC14 | Common | No | $+/+$ | $262-272^{*}$ |  |
|  | 1D3 | Common | Yes | $+/+$ | $1-29^{*}$ |



Figure S1. Selected Abs and epitope residues with associated experimental data. Communities are colored on the structure of gD . Orange represents nectin binding region. Face \#1 is the nectin binding face. Faces \#2-4 are rotated by 90,180 , and 270 degrees around the $y$-axis. Face \#5 is the view from above and Face \#6 is the view from below.

Table S1. Agreement between epitope residues targeted by our control antibody, E317, according to the crystal structure vs. those identified from our dock binning based approach.

| Crystal <br> Structure | Focused <br> Docking |
| :---: | :---: |
| Gln27 | Gln27 |
| Tyr38 | Tyr38 |
| Gln132 | Gln132 |
| Asp139 | Asp139 |
| Ser140 | Ser140 |
| Asp215 | Asp215 |
| Pro221 | Pro221 |
| Arg222 | Arg222 |
| Phe223 | Phe223 |
| Ile224 |  |
| Asn227 |  |
| Val231 |  |
| Ser235 |  |
| Ile238 | Ile238 |

